READY

SET

ZEGALOGUE

COMING SOON

ZEGALOGUE^®

(dasiglucagon) injection

NOW APPROVED

ZEGALOGUE is the first and only glucagon analog for the treatment of severe hypoglycemia in adults and children with diabetes aged 6 years and older

ZEGALOGUE will be available to prescribe soon

Sign up below to receive updates

Get ready for what’s next for your patients with diabetes

Sign up to receive updates on ZEGALOGUE, as well as information on how to prepare your patients and their caregivers for severe hypoglycemia.

First name*(Insert first name)

Last name*(Insert last name)

Email*(Insert email)

Phone number(Insert phone number)

Specialty*(Select specialty)

Zip code*(Insert zip code)

This field is required.

I agree to the statement below and have read and understand the Terms of Use and Privacy Policy.

You are now registering for information that is intended for healthcare professionals. By registering at this site, you certify that you are a healthcare professional licensed in the United States, or its territories, and are indicating that you wish to receive information about current Zealand products, related future FDA-approved product information from Zealand Pharma or its affiliates, and general information from Zealand Pharma including information on clinical programs, products and services. It is Zealand Pharma’s intent to provide information only to healthcare professionals licensed in the United States or its territories.

By completing and submitting this form, you agree to allow Zealand Pharma, its affiliates and its agents to collect the information provided and to be contacted by Zealand, its affiliates and its agents, including third-party companies working with Zealand Pharma by mail, email, fax, telephone call or text message, including autodialed and prerecorded calls and messages, now and in the future, regarding information about Zealand Pharma’s products, services, and other programs or topics of interest, as well as for marketing purposes, to conduct market research or otherwise ask me about my experience with, or thoughts about, such topics. I understand and agree that any information that I provide may be used by Zealand Pharma, and its affiliates and agents, including third-party companies working with Zealand Pharma, to help develop and improve products, services and programs. I understand that my consent is not required as a condition of purchasing or receiving any goods or services from Zealand Pharma. Zealand Pharma will not sell, rent or otherwise distribute or transfer your personally identifiable information to any unrelated third party for marketing purposes without your express permission, and will use your information in accordance with its Privacy Policy. I understand that I may revoke this permission and choose to no longer receive information from Zealand Pharma by clicking the “unsubscribe” link provided in the emails I receive from Zealand Pharma.

*Required.

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION

ZEGALOGUE (dasiglucagon) injection is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above.

IMPORTANT SAFETY INFORMATION

Contraindications

ZEGALOGUE is contraindicated in patients with pheochromocytoma because of the risk of substantial increase in blood pressure and in patients with insulinoma because of the risk of hypoglycemia.

INDICATION

ZEGALOGUE (dasiglucagon) injection is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above.

IMPORTANT SAFETY INFORMATION

Contraindications

ZEGALOGUE is contraindicated in patients with pheochromocytoma because of the risk of substantial increase in blood pressure and in patients with insulinoma because of the risk of hypoglycemia.

Warnings and Precautions

ZEGALOGUE is contraindicated in patients with pheochromocytoma because glucagon products may stimulate the release of catecholamines from the tumor. If the patient develops a substantial increase in blood pressure and a previously undiagnosed pheochromocytoma is suspected, 5 to 10 mg of phentolamine mesylate, administered intravenously, has been shown to be effective in lowering blood pressure.

In patients with insulinoma, administration of glucagon products may produce an initial increase in blood glucose; however, ZEGALOGUE administration may directly or indirectly (through an initial rise in blood glucose) stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. ZEGALOGUE is contraindicated in patients with insulinoma. If a patient develops symptoms of hypoglycemia after a dose of ZEGALOGUE, give glucose orally or intravenously.

Allergic reactions have been reported with glucagon products; these include generalized rash, and in some cases anaphylactic shock with breathing difficulties and hypotension. Advise patients to seek immediate medical attention if they experience any symptoms of serious hypersensitivity reactions.

ZEGALOGUE is effective in treating hypoglycemia only if sufficient hepatic glycogen is present. Patients in states of starvation, with adrenal insufficiency or chronic hypoglycemia may not have adequate levels of hepatic glycogen for ZEGALOGUE administration to be effective. Patients with these conditions should be treated with glucose.

Adverse Reactions

The most common adverse reactions (≥2%) associated with ZEGALOGUE in adults were nausea, vomiting, headache, diarrhea and injection site pain; in pediatrics: nausea, vomiting, headache and injection site pain.

Drug Interactions

Patients taking beta-blockers may have a transient increase in pulse and blood pressure when given ZEGALOGUE. In patients taking indomethacin, ZEGALOGUE may lose its ability to raise blood glucose or may produce hypoglycemia. ZEGALOGUE may increase the anticoagulant effect of warfarin.

Please click here for Full Prescribing Information.

Reference: Zegalogue (dasiglucagon). Prescribing information. Zealand Pharma A/S; March 2021.

Are you a healthcare professional?

The information in this section of ZEGALOGUE.com/hcp is intended for US healthcare professionals only.

YES

Are you ready to leave?

You are now leaving ZEGALOGUE.com/hcp.

By clicking the “Continue” button below, you will be taken to a website that may contain links or references to other websites in which our privacy policy may not apply. We encourage you to read the privacy policy of every website you visit. By clicking the “No thanks” button below, you will be taken to the page you were on previously.

CONTINUE

NO THANKS

READY

SET

ZEGALOGUE

COMING SOON

ZEGALOGUE®

(dasiglucagon) injection

NOW APPROVED

ZEGALOGUE is the first and only glucagon analog for the treatment of severe hypoglycemia in adults and children with diabetes aged 6 years and older

ZEGALOGUE will be available to prescribe soonSign up below to receive updates

Get ready for what’s next for your patients with diabetes

INDICATION AND IMPORTANT SAFETY INFORMATION

INDICATION

IMPORTANT SAFETY INFORMATION

Contraindications

INDICATION

IMPORTANT SAFETY INFORMATION

Are you a healthcare professional?

Are you ready to leave?

ZEGALOGUE^®

ZEGALOGUE will be available to prescribe soon

Sign up below to receive updates